Australia markets open in 9 hours 40 minutes

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.09-0.22 (-1.79%)
At close: 04:00PM EST
12.12 +0.03 (+0.25%)
Pre-market: 08:16AM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.31
Bid0.00 x 3100
Ask0.00 x 2200
Day's range12.07 - 12.53
52-week range12.07 - 18.86
Avg. volume8,755,674
Market cap14.622B
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)-1.72
Earnings date08 Nov 2021
Forward dividend & yield0.44 (3.57%)
Ex-dividend date22 Nov 2021
1y target est20.38
  • PR Newswire

    Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent

    Viatris Inc. (NASDAQ: VTRS) today announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.

  • Motley Fool

    Is It Too Late to Buy Viatris Stock?

    If you're a fan of stable healthcare companies that have the potential to pay you ever-rising dividends until the cows come home, Viatris (NASDAQ: VTRS) might well become a dream stock. The single most persuasive argument against it being too late to buy Viatris is that the company is just getting started. After all, its life as an independent entity started a mere year ago with the merger of Pfizer's generic drugs business, Upjohn, and Mylan.

  • Motley Fool

    3 Pharma Stocks That Are Too Cheap to Ignore

    Here's why they think Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS) are too cheap to ignore. Prosper Junior Bakiny (Bristol Myers Squibb): Investors are sometimes wary of undervalued companies.